Home Biosimilar Antibodies Immunology & Inflammation PD-1/PD-L1 -VEGFR Pm8002 (Anti-PD-L1 & VEGF)
For research use only. Not for use in humans.

Pm8002 (Anti-PD-L1 & VEGF)

Synonyms: BNT327

Pm8002 is a bispecific antibody targeting both PD-L1 and VEGF-A, with potential immune checkpoint inhibition, anti-angiogenic, and antineoplastic activities. It demonstrates promising antitumor effects in patients with previously treated platinum-resistant recurrent ovarian cancer (PROC) or cervical cancer, as well as in those with advanced solid tumors. MW : 172.48 KD.

Pm8002 (Anti-PD-L1 & VEGF)

Quality Control

Batch: A400301 Purity: 99% Protein concentration: 9.36mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation PD-1/PD-L1 interaction PD-1 PD-L1 PD-1/PD-L1 Others
GS-4224 0
INCB086550 1
BMS-1001 0
BMS-1166 8
PD-1/PD-L1 Inhibitor 3 13
BMS-1 13
BMS-202 26
CA-170 (AUPM-170) 0
SR 0987 1 IL17,RORγt
Spartalizumab (anti-PD-1) 3
Camrelizumab (anti-PD-1) 2
AUNP-12 3
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Pm8002 is a bispecific antibody targeting both PD-L1 and VEGF-A, with potential immune checkpoint inhibition, anti-angiogenic, and antineoplastic activities. It demonstrates promising antitumor effects in patients with previously treated platinum-resistant recurrent ovarian cancer (PROC) or cervical cancer, as well as in those with advanced solid tumors. MW : 172.48 KD.

Product Details

CAS No. N/A
Source CHO
Storage
(From the date of receipt)		 -80℃(avoid freeze-thaw cycles)

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.